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Introduction: Dopamine replacement therapy for Parkinson’s disease (PD) was recently 
linked to the development of impulse control disorders such as pathological gambling (PG), 
hypersexuality, compulsive shopping, and binge or compulsive eating. Antiglutamatergic agents 
including amantadine (Ama) reduce these behaviors in PD and non-PD patients. The aim of our 
study is to evaluate the changes in executive functions, emotions, and reward/loss processing 
during Ama treatment in PD patients.
Methods: Thirty-three patients affected by idiopathic PD were selected from a cohort of 
1,096 PD patients and categorized in three different groups: ten affected by PG (PD-PG); nine 
PD patients with other impulse control disorder (PD-ICD); and 14 PD patient without any 
psychiatric disorder (PD-CTR-controls). For the neuropsychological evaluation, the follow-
ing behavioral tasks where administered: the Stroop, the emotional Stroop, and the monetary 
reward/loss risk-taking tasks.
Results: During Ama treatment, PD-PGs showed a decrease in risky choices and an increase 
in non-risky choices (t(9)=−2.40, P,0.05 and t(9)=2,67, P,0.05 uncorrected, respectively). 
Between-group comparison showed a significant decrease in risky choices for PD-PG with respect 
to PD-CTR (t(22)=−4.16, P,0.01), and a decreased accuracy for positive words in comparison 
between PD-PG and PD-ICD (t(17)=−7,49, P,0.01) and PD-PG and PD-CTR (t(22)=−4.29, 
P,0.01). No within- and between-group differences were observed for Stroop task.
Discussion: Our data showed that Ama add-on therapy reduces hypersensitivity to reward 
and sustains activation toward uncertainty in PD-PG patients. These finding might explain the 
behavioral mechanism underlying the effect of antiglutamatergic drugs.
Keywords: Parkinson’s disease, executive functions, emotion
Introduction
Nonmotor symptoms occur across all Parkinson’s disease (PD) stages. The symptoms 
are unrecognized, underestimated, and under-treated or not treatable.1
Dopamine replacement therapy for PD was recently related to aberrant or excessive 
dopamine receptor stimulation resulting in the development of a number of nonmotor 
behavioral control problems,2 which consist of a set of complex disinhibitory patholo-
gies such as impulse control disorders (ICDs). ICDs, and in particular pathological 
gambling (PG), represent a significant clinical concern in PD patients, as described 
by Housden et al.3
These behavioral addictions are clinical entities in which repetitive impulsive 
behaviors occur, with negative effects on the patients’ and their relatives’ lives; the 
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prominent features of such conditions are: cognitive salience, 
as the activity dominates the subject’s thoughts and behaviors; 
conflict with other persons or activities; euphoria or relief, 
a feeling of short term pleasure from engaging in the behavior; 
tolerance or loss of control over the behavior; withdrawal, as 
experiencing unpleasant feelings when unable to engage in 
the behavior; and relapse and reinstatement, indicated when 
people unsuccessfully attempt to cut down on the behavior and 
subsequently engage in similar or higher levels of the activity 
than they had previously. Behavioral addictions are rather 
common in the general population, with a wide diffusion from 
adolescents4 to geriatric age.5 The impairment of functioning, 
with the presence of impulsiveness and other psychiatric 
symptoms, can be relevant and distressing in PD.6
In PD, typical ICDs include hypersexuality, PG, com-
pulsive shopping, and/or compulsive eating; 6%–7% 
of PD patients meet criteria for one of these disorders.3 
 Lifetime prevalence of ICDs is 6.1% in all PD patients, and 
13.7%–17.1% in PD patients on dopamine agonists (DA).2,7 
The burden of these symptoms results in a negative impact 
on quality of life for patients and relatives.1
Diagnostic and Statistical Manual of Mental Disorders 
Fifth Edition (DSM-5) recently inserted PG among the group 
defined as “Addiction and related problems”; it refers to 
persistent and recurrent gambling behavior characterized by 
preoccupation with gambling, increasing amounts of money 
spent, unsuccessful attempts to control gambling, restlessness 
or irritability when cutting down on gambling, lying to others 
about gambling, work or education, and relying on others for 
money. PG is the most extensively studied ICD in both PD 
and non-PD populations.8,9
Pathophysiology and evaluation
Neuroimaging studies observed alterations in the ventro-
medial prefrontal cortex (VM-PC) and the corticobasal-
ganglionic-thalamic circuit in PD patients. Single-photon 
emission computed tomography (SPECT) studies found a 
dysfunction of the mesolimbic regions in PD with PG,10–12 and 
alteration of these pathways were shown in non-PD patients 
with PG, showing a reduced activity during rewarding events 
and monetary-reward tasks.13–15 Furthermore, the Stroop color 
word task16 showed reduced activity in VM-PC in poor PG 
patients. Stroop and memory task alterations were shown in 
PD patients with hypersexuality. PD patients with ICDs were 
impaired on spatial planning and set-shifting tests compared 
with healthy controls.17 The involvement of the prefrontal 
cortex (PC) suggests that tasks to assess executive functions 
are the best method to study PG and ICD in patients.
Recent studies hypothesize that levodopa-induced 
dyskinesias (LIDs) and behavioral alterations observed in 
dopamine dysregulation syndrome and ICD2,18 depend on 
common mechanisms involving alterations of glutamate 
homeostasis with combined activation of sensitized dopamine 
and NMDA glutamatergic receptors.19 Pre- and postsynaptic 
mechanisms are implicated in the devolvement of LIDs and 
ICDs, the first based on alterations in dopamine transmis-
sion after chronic administrations and the second because 
of excessive expression and sensitization of D1 receptors in 
striatonigral neurons.2,20 The neuronal adaption underlying 
the imbalance between synaptic and nonsynaptic glutamate 
might result in failure of PC control.
Yet no treatments are at present validated for ICDs or 
dopamine dysregulation syndrome; reduction or withdrawal 
of DA are considered possible options, but may induce 
severe worsening of motor control and DA withdrawal 
syndrome.21,22
Amantadine (Ama) is L-amino-adamantanamine, a salt of 
the symmetric 10-carbon primary amine. Its mechanism of 
action is based on interaction with dopamine, by enhancing 
release and inhibiting its reuptake and by changing dopamine 
receptor affinity, and on NMDA glutamate receptor blockade, 
normalizing the activity of the glutamatergic corticostriatal 
and subthalamic-pallidal pathways. As shown for other 
antiglutamatergic drugs, Ama reduces LIDs to the point that 
its effect on LIDs is considered by Cochrane reviews and a 
recent treatment guideline23 as having the only class I level 
A evidence of efficacy23,24 for Ama.
In a recent study, we investigated the possible efficacy 
of Ama in the control of PG associated with PD.9 The study 
was conducted in a double-blind cross-over manner with 
Ama 200 mg/day versus placebo and an open follow-up. 
 Assessments included PG specific scales (Yale–Brown 
obsessive compulsive scale, South Oaks Gambling Screen 
[SOGS]) as well as assessment of expenditures and time 
spent gambling. Ama abolished or reduced PG in all treated 
patients, as confirmed by scale score and daily-expenditures 
reduction.
Also, the antiglutamatergic drug acamprosate ([Aca] 
Ca-acetyl homotaurine), a drug clinically used to reduce 
alcohol dependence and craving, attenuates glutamate 
release within the nucleus accumbens by binding to GluR5 
AMPA receptors and interacting with NMDA receptors. 
A recent study showed that acamprosate significantly 
reduced obsessive-compulsive behavior in binge eating and 
food craving, and improved quality of life in patients affected 
by binge eating disorder.
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Therefore, a possible option for ICDs and LIDs treatment 
might be to consider antiglutamatergic drugs.23 However, few 
molecules are characterized by efficient antiglutamatergic 
activity;25 for example, memantine,26,27 Dextrometrophan,28 
and budipine are considered antiglutamatergic drugs, yet 
only anecdotal reports showed LIDs or ICDs reduction. Lam-
otrigine, oxcarbazepine, and topiramate represent a class of 
anticonvulsant compounds with glutamate-release-inhibiting 
properties that shows encouraging evidence as novel medica-
tions for alcoholism.29,30  However, their potential in ICDs 
still needs to be demonstrated.
In our study, which considers a subsample of PD 
patients with ICDs previously described elsewhere,9,31 we 
tested before (T0) and after (T1) Ama add-on medication 
(200 mg/day) to assess its effect on executive functions, emo-
tion, and reward and loss processing. The color word Stroop 
task, emotional Stroop task (EST), and monetary reward/loss 
task slot machine-like game, respectively, were used to test 
the effect of Ama in PD patients with PG (PD-PG) and PD 
patients with ICDs (PD-ICD). 
Materials and methods
study population
A cohort of 1,096 patient with diagnosis of idiopathic PD 
according to UK-BBC32 were regularly followed and treated 
from January 2011 to March 2012 in our Movement Dis-
order Clinic; they were asked to participate in the study. 
Inclusion criteria were: idiopathic PD; aged between 18 and 
80 years; ascertained dopaminergic response; patients will-
ing and able to give written informed consent; patients will-
ing and able to comply to the study procedures; stable dose 
of dopaminomimetic drugs for at last 28 days; diagnosis of 
PD-PG for group A, and diagnosis of PD-ICD for group 
B (diagnosis according to DSM, 4th edition [DSM-IV] 
text revision, Questionnaire for Impulsive-Compulsive 
Disorders in Parkinson’s Disease-Rating Scale, a rating 
scale designed to measure severity of symptoms and sup-
port a diagnosis of impulse control disorders and related 
disorders in PD).33 Group C was PD control (PD-CTR) 
without PG or ICD.
Exclusion criteria were: history or signs suggesting atypi-
cal or secondary parkinsonism; history of stereotactic brain 
surgery for PD; mini–mental state examination (MMSE) 
score less than 24 at screening; any medical or psychiatric 
condition (other than ICD) that may compromise the patient’s 
participation in the study; women with child-bearing poten-
tial; history of antipsychotics or anticholinergics medication 
and previous treatment with Ama.
Thirty-three patients (six females) with idiopathic PD met 
the inclusion/exclusion criteria. PG was identified according 
to DSM-IV (rule of five of nine items) and SOGS criteria.34 
PD patients were grouped on the basis of DSM-IV text 
revision criteria for ICDs and PG. PD patients were divided 
into three different groups: group A consisted of ten PD 
patients affected by pathological gambling (PD-PG; mean 
age 60.6±6.8 years); group B consisted of nine PD patients 
with other ICDs such as compulsive shopping, hypersexual-
ity, and binge eating (ICD-PD; mean age 59.3±6.8 years); 
and group C consisted of 14 PD patients without PG or 
ICD (PD-CTR; mean age 59.0±9.5 years). Patients were 
matched for age, education, disease stage and duration, and 
dopaminomimetic therapy according to their need. None of 
the patients presented with LID.
According to our clinical procedures, all patients were 
evaluated with the Unified Parkinson’s Disease  Rating Scale,35 
PD stage was assessed with the Hoehn/Yahr scale,36 and all 
patients underwent MMSE neuropsychiatric  evaluation.37 
The study was approved by the University of Chieti ethics 
committee and was carried out according to the declaration 
of Helsinki and subsequent revisions. Patients (or caregivers) 
signed a written informed consent.
In order to understand whether the effect of antigluta-
matergic drugs in ICD is dependent on modulation of execu-
tive functions or on processing of emotions and reward/loss, 
we assessed the effect of Ama as add-on therapy with the 
color word Stroop task, EST, and monetary reward/loss task 
slot machine-like game in PD-PG, ICD-PD, and PD-CRT. 
The patients were evaluated at T0 and T1, add-on medication 
(200 mg/day), following an opportune up and down titra-
tion. The neuropsychological tasks were performed at T0 
and T1, also at the same time when the patients presented 
optimal motor performance and in “on” phase.
Tasks and stimuli
Tasks were given to all participants in a randomized order and 
performed at T0 and T1. Each participant performed tasks 
after the task had been explained in-depth. Task stimuli were 
presented on a computer by using MATLAB software.
Monetary reward/loss risk-taking task
Given the participants, we chose to make the task very simple 
to avoid stress derived from difficult instructions. Based on 
previous studies on PG,14,15 we chose a non-realist gambling 
task. The task, is able to observe processes underlying 
 addictive behavior and to measure indirectly the functioning 
of the front-striatal pathway in PD-PG.38
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The task we used was a version of a slot-machine game 
where participants were asked to bet 50€ (high reward) or 
5€ (low reward) on a random drawn square. There were two 
squares: a red square representing a winning bet and a black 
square representing a losing bet. The goal of the game was to 
win as much money as possible. The task was divided in three 
within-subjects randomized subsessions, the first with a 75% 
probability of winning, the second with a 50% probability of 
winning, and the third with a 25% probability of winning. For 
data analysis, we considered risky choices the bet of 50€ on 
losing squares. Choices and reaction times were collected.
stroop task
The classic Stroop test relies on the observation that color 
naming can be slowed by the concomitant presence of a 
color word (competing information). The task requires 
participants to respond to the ink color and suppress the 
more familiar word identity. Whilst responses in congruent 
settings are relatively automatic, incongruence between the 
letters and ink color requires keen attention and leads to 
slower responses.39,40
Each trial consisted of a fixation cross at the center of a 
grey screen (500 ms), followed by word stimulus (500 ms), 
and then by an interstimulus interval ([ISI] 3,000 ms). During 
ISI, participants were instructed to press a key corresponding 
to the color (red or green) of the word that appeared on the 
screen with both speed and accuracy. The task comprised four 
blocks (100 trials), with half of the trials being incongruent 
(eg, the word “red” printed in the color green) and half being 
congruent (eg, the word “red” printed in the color red). Color 
words and ink colors selected for use in this study included 
red, green, and black. Presented trial type was randomized, 
though each participant completed 40 of each possible trial 
type (both congruent and incongruent trials using each of the 
three possible colors) until the end of the task. Participants 
were initially exposed to a 20-trial practice block.
emotional stroop task
EST is widely used to investigate attentional bias and 
 interference caused by emotionally salient stimuli.40 The 
task presented neutral and emotionally charged stimuli 
(neutral and emotionally-negative/-positive words) with three 
 different colors (black, red, and green), and the patients were 
asked to press the button corresponding to the color of the 
word as quickly as possible.
Color naming EST was designed based on previous 
studies.41–43 Neutral, negative, and positive words were selected 
on the basis of norms in the Italian language, ie, emotionality, 
familiarity, and statistical frequency. The task contained 111 
trials presented in three blocks of 37 words each (three different 
words for each word type). The word stimuli were presented 
for 500 ms and the ISI was 3,000 ms. The color-identification 
response latency for each stimulus was recorded (Figure 1).
Data analysis
Statistical analysis was performed using Statistica®, Version 
6.0 (StatSoft, Inc., Tulsa, OK, USA). Results of the Stroop 
task were analyzed as follows: the mean reaction times and 
percentage of correct responses (accuracy) for each stimulus 
(congruent and incongruent, respectively) was computed; 
then, three different two-tailed t-tests were computed for 
each group for the T0 and T1 to assess the effect of add-on 
therapy.
Results for EST Task were analyzed, computing mean 
reaction times and accuracy for positive and negative words. 
Two tailed t-tests were computed for each PD group at T0 
and T1.
Results for the monetary reward/loss task were analyzed 
by computing the percentage of risky and non-risky choices. 
Three different two-tailed t-tests were performed to assess 
the effect of add-on therapy.
Between-group comparison was performed for T0 
and T1 separately for each task. Where possible, Bonferroni 
 correction was applied to t-test results.
Results
Thirty-three patients (six females) with idiopathic PD met 
the inclusion/exclusion criteria. PD patients were divided 
into three different groups: ten PD-PG (mean age: 60.6±6.8 
years); nine PD-ICD (mean age 59.3±6.8 years) ; and 14 PD 
patients without PG or ICD (PD-CTR) (mean age 59.0±9.5). 
As shown in Table 1, patients were not different in age, edu-
cation, disease stage and duration, and dopaminomimetic 
therapy according to their need. UPDRS III scores were not 
different between groups. MMSE evaluation did not show 
a significant cognitive decline (MMSE .24). SOGS scores 
indicated the presence of pathological gambling in group A, 
while in the other group the scores were under the cut-off for 
pathological gambling. On the YBOCS, scores indicating the 
presence of obsessive-compulsive behaviors were reported 
in the PD-PG and PD-ICD groups. On the QUIP-R scale, 
scores showed impulse-control behavior in the PD-PG and 
PD-ICD groups.
No significant between- and within-group differences 
were observed in mean reaction times for the three different 
tasks. Data for within-group results are shown in Table 2.
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Risk-taking task
Win
Green
Red
Response
3,000 ms
Positive stimuli
500 ms
Emotional Stroop task
Response
3,000 ms
Incongruent stimuli
500 ms
Neutral stimuli
500 ms
Acqua
+
Vita
+ +
BlackGreen
Red
Pace
Giola
+
Casa
Stato
Congruent stimuli
500 ms
Black
Stroop taskB
A
Feedback
3,000 ms
Lose
Betting
50 5
1,500 ms
Figure 1 Psychological tasks.
Notes: (A) Detailed procedure of a risk-taking task. (B) Detailed procedure of the stroop task and the emotional stroop task.
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At T0, results from the risk-taking task, Stroop task, and 
EST were not different between groups.
At T1, results from the risk-taking task showed a decrease 
in risky choices and increase in non-risky choices (t(9)=−2.40, 
P,0.05 and t(9)=2.67, P,0.05 uncorrected, respectively) in 
PD-PG patients. Between-group comparison of PD-PG ver-
sus PD-CRT showed a significant decrease in risky choices 
for the PD-PG group (t(22)=−4.16, P,0.01).
At T1, results from the Stroop task did not show within- 
and between-group differences. Interestingly, we did not 
observe modifications in the accuracy.
At T1, our results for the EST showed a significant decrease 
in accuracy for positive words in the PD-PG and PD-ICD 
groups (t(9)=−15.83, P,0.05 corrected and t(8)=−2.7, P,0.05 
uncorrected, respectively), while a significant increase was 
observed to negative words in the PD-ICD group (t(9)=−2.40, 
Table 1 Patient demographics
Group A 
PD-PG  
(n=10)
Group B 
PD-ICD  
(n=9)
Group C 
PD-CTR  
(n=14)
age (years)/male sex 60.6±6.8/7 59.3±6.8/6 59.0±9.5/7
education (years) 11.7±2.6 10.3±3.2 11.7±1.9
Disease duration (months) 28.2±12.3 29.0±8.5 27.2±8.4
UPDrs iii 20.5±6.8 21.4±4.2 21.6±6.9
hoehn/Yahr stage 1.9±0.2 1.7±−0.3 1.7±0.02
MMse 28.5±2.1 28.4±1.9 28.6±2.0
sOgs 13±2.5 4±0.5 0.8±0.3
YBOcs 9.3±3.8 8.3±7.8 2.1±0.9
Quip-rs 37.5±15.1 51.0±11.1 5.00±3.5
l-dopa equivalent dose (mg) 294.5±123.1 283.3±132.9 307±96.3
Abbreviations: cTr, control; icD, impulse control disorder; l-dopa, l-3,4-
dihydroxyphenylalanine; MMse, mini–mental state examination; PD, Parkinson’s 
disease; PG, pathological gambling; Quip-RS, Questionnaire for Impulsive-Compulsive 
Disorders in Parkinson’s Disease-Rating Scale; SOGS, South Oaks Gambling Screen; 
UPDRS III, unified Parkinson’s disease rating scale motor part; YBOCS, Yale–Brown 
obsessive compulsive scale.
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Table 2 Within-subjects task results
Group Condition Time Mean SD t-value df P-value
risk taking task
 PD-Pg risk T0 42.8 16.4
T1 28.7 16.2 2.40 9 0.039
No risk T0 40.6 13.8
T1 56.4 21.6 −2.67 9 0.025
 PD-icD risk T0 46.3 5. 6
T1 40.2 12.3 1.46 8 0.181
No risk T0 40.7 5.7
T1 49.7 18.2 −1.30 8 0.229
 PD-cTr risk T0 42.5 18.4
T1 46.3 0.9 −0.84 13 0.413
No risk T0 43.9 16.6
T1 52.4 1.8 −1.84 13 0.088
stroop task
 PD-Pg congruent T0 85.7 15.5
T1 83.1 14.3 0.32 9 0.75
incongruent T0 88.9 7.1
T1 91.6 8.1 −0.80 9 0.442
 PD-icD congruent T0 88.3 6.6
T1 88.3 16.6 0.00 8 1
incongruent T0 93.9 3.1
T1 90 17.4 0.72 8 0.489
 PD-cTr congruent T0 85.7 15.5
T1 81.4 21.4 1 13 0.33
incongruent T0 84.3 14.2
T1 82.8 14.1 1 13 0.33
emotional stroop task
 PD-Pg Negative T0 65.6 7.3
T1 68.8 3.7 −1.92 9 0.086
Positive T0 64 8
T1 29.3 3.9 15.83 9 0.000
 PD-icD Negative T0 67.1 3.3
T1 70.8 1.7 −2.78 8 0.023
Positive T0 70.7 2.8
T1 40 1.9 25.03 8 0.000
 PD-cTr Negative T0 64 10.2
T1 66.8 6.5 −1.11 13 0.28
Positive T0 66 5.4
T1 56.8 19.8 −1.12 13 0.28
Abbreviations: CTR, control; ICD, impulse control disorder; PD, Parkinson’s disease; PG, pathological gambling; SD, standard deviation; T0, before amantadine add-on 
medication; T1, after amantadine add-on medication; df, degrees of freedom.
P,0.03 uncorrected). PD-PG patients showed a decrease in 
accuracy for positive words compared to the PD-ICD group 
(t(17)=−7.49, P,0.01) and PD-CTR group (t(22)=−4.29, 
P,0.01). Results are shown in detail in Figure 2.
Discussion
The purpose of our study was to assess the effect of Ama 
add-on therapy on executive functions, emotions, and pro-
cesses underlying reward and loss in PD-PG and PD-ICD. 
Ama is one of the possible pharmacological treatments for 
PD and non-PD patients with PG as has been shown in recent 
studies.9,44 The main outcome of the present study was to 
evaluated the efficacy of Ama in improving ICDs in PD-PG 
and PD-ICD patients using neuropsychological tasks at time 
T0 and T1 in the three patient groups.
The main outcome of this study was to assess the effi-
cacy of Ama in improving the selection of non-risky choices 
in the risk-taking task in PD-PG patients and the increase 
in accuracy to negative words in the PG-ICD group.
The significant reduction of risky choices after treatment 
observed in this study may represent a protective factor that 
is able to reduce the number of relapses in subjects with PG. 
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Amantadine and cognitive flexibility
Reduction of risky choices could be considered the focal 
process responsible for the efficacy of Ama in PD-PG, previ-
ously described in other studies.9,44
Our data highlight a modified behavior in PD-PG patients 
after introduction of Ama; in other PD patients (PD-ICD/PD-
CTR), performance was unchanged and executive function, 
specifically inhibition processing, was not affected. 
In all PD patients, the Stroop task we performed did not 
show changes in accuracy, indicating that there is no defi-
ciency in inhibition of interference, as shown by Kertzman.45 
Previous literature shows contradictory results regarding 
executive functions, PD-PG and PD-ICD patients data, and 
the relationship between executive functions and PG or other 
ICDs in PD patients.46,47
The differences observed in the Stroop task and EST at 
T1 indicate the involvement of different inhibitory processes 
during the execution of the task.48 For the EST, we found at 
T1 in PD-ICD a decrease in accuracy for positive words and 
an increase in accuracy for negative words, while PD-PG 
showed a decrease in accuracy for positive words.
Previous studies where EST was used indicated that the 
level of activation or performance for emotional words was 
higher than for neutral words, resulting in a decreased ability 
to inhibit the processing of emotional meaning.49,50 The higher 
performance relative to negative words may depend on the 
automatic vigilance effect.51 The automatic vigilance effect is 
an innate mechanism that normally allows a person to direct 
attention to negative or dangerous stimuli, having a high 
adaptive value. Automatic vigilance seems to be more active 
during experimental tasks like EST in healthy subjects.51
Between-group comparison for the post-treatment period 
showed decreased accuracy in recognizing positive words 
in PD-PG and PD-ICD patients. The possible effect of Ama 
may be the enhancement of the automatic vigilance effect 
in PD-PG and PD-ICD patients. This is in line with our 
results.
A relevant limitation of this study is the small sample 
size and the consequent low statistical power, but levels of 
significance have been found, confirming the strength of 
the data.
A theoretical limitation is represented by two previous 
studies using a cross-sectional or retrospective design,8,52 
which did not evidence a statistical reduction of PG in 
patients treated with Ama. Yet, cross-sectional or retrospec-
tive studies are subject to treatment and recall bias, and 
can only identify the prevalence and clinical correlates of 
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Figure 2 Within-group results.
Notes: graphs show percentage of risky and non-risky choices in risk-taking task, and accuracy in Stroop task and emotional Stroop task, respectively, before (0) and after 
(1) amantadine add-on therapy. Vertical bars indicate standard deviations. *P,0.05; **P,0.0001.
Abbreviations: cTr, control; ICD, impulse control disorder; PD, Parkinson’s disease; PG, pathological gambling; resp, response.
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ICDs, but not their incidence or risk factors; as such these 
are not sufficient evidence of efficacy or lack of efficacy 
of a drug.53
Any new treatment calls for validations and further 
study designs. Taking as an example the history of L-3,4-
dihydroxyphenylalanine treatment, the initial evidence of 
L-3,4-dihydroxyphenylalanine benefits in PD were chal-
lenged by reports showing its inefficacy or side effects; the 
key to efficacy was patient selection and dose finding.54 The 
lack of studies due to inappropriate patient selection is mis-
leading and represents one of the major problems in clinical/
pharmacological research,8,55,56 particularly in PD, where the 
clinical presentation and the variety of symptoms – ranging 
from hallucinations to motor and sleep-behavior problems – is 
large.31,57 In our recent study,9 the obvious prerequisite was 
the absence of prior exposure to Ama, whereas in cross-
sectional observational studies, the history of Ama intake, of 
psychosis and tachyphylaxis are well known effects of Ama, 
were not considered.
Further research with larger clinical trials are needed to 
assess the role of antiglutamatergic drugs in the treatment 
of ICDs in PD.
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